{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', \"Investigator's Brochure. (2017). Investigator's brochure for teprotumumab (HZN-001), human\", 'anti-IGF-1 receptor antibody, for ophthalmic indications including thyroid eye disease; 7th', 'edition. Horizon Pharma USA.', \"Kahaly GJ. (2010). Management of moderately severe Graves' orbitopathy. In W. M. Wiersinga\", \"& G. J. Kahaly (Eds.), Graves' orbitopathy: a multidisciplinary approach - questions and\", 'answers (2nd ed.): Karger Basel.', \"Kahaly GJ, Petrak F, Hardt J, et al. Psychosocial morbidity of Graves' orbitopathy. Clinical\", 'endocrinology. 2005; 63(4): 395-402.', 'Mallika P, Tan A, Aziz S, et al. Thyroid associated ophthalmopathy - a review. Malaysian family', 'physician : the official journal of the Academy of Family Physicians of Malaysia. 2009; 4(1): 8-', '14.', 'Melamud B, Lurie Y, Goldin E, et al. Methylprednisolone-induced liver injury: a diagnostic', 'challenge. The Israel Medical Association journal : IMAJ. 2014; 16(3): 180-1.', 'Mostbeck A, Galvan G, Bauer P, et al. The incidence of hyperthyroidism in Austria from 1987 to', '1995 before and after an increase in salt iodization in 1990. European journal of nuclear', 'medicine. 1998; 25(4): 367-74.', 'Mourits MP, Koornneef L, Wiersinga WM, et al. Clinical criteria for the assessment of disease', \"activity in Graves' ophthalmopathy: a novel approach. The British journal of ophthalmology.\", '1989; 73(8): 639-44.', 'Naik VM, Naik MN, Goldberg RA, et al. Immunopathogenesis of thyroid eye disease: emerging', 'paradigms. Survey of ophthalmology. 2010; 55(3): 215-26.', \"Noth D, Gebauer M, Muller B, et al. Graves' ophthalmopathy: natural history and treatment\", 'outcomes. Swiss medical weekly. 2001; 131(41-42): 603-9.', 'Perez A, Jansen-Chaparro S, Saigi I, et al. Glucocorticoid-induced hyperglycemia. Journal of', 'diabetes. 2014; 6(1): 9-20.', 'Poetker DM, Reh DD. A comprehensive review of the adverse effects of systemic', 'corticosteroids. Otolaryngologic clinics of North America. 2010; 43(4): 753-68.', 'Pritchard J, Han R, Horst N, et al. Immunoglobulin activation of T cell chemoattractant', \"expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like\", 'growth factor I receptor pathway. Journal of immunology (Baltimore, Md : 1950). 2003;', '170(12): 6348-54.', 'Prummel MF, Terwee CB, Gerding MN, et al. A randomized controlled trial of orbital', \"radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. The Journal\", 'of clinical endocrinology and metabolism. 2004; 89(1): 15-20.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 113 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', \"Prummel MF, Wiersinga WM. Smoking and risk of Graves' disease. Jama. 1993; 269(4): 479-82.\", 'Salvi M, Vannucchi G, Curro N, et al. Efficacy of B-cell targeted therapy with rituximab in', \"patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. The\", 'Journal of clinical endocrinology and metabolism. 2015; 100(2): 422-31.', 'Silkiss RZ, Reier A, Coleman M, et al. Rituximab for thyroid eye disease. Ophthalmic plastic', 'and reconstructive surgery. 2010; 26(5): 310-4.', 'Smith TJ. Insulin-like growth factor-I regulation of immune function: a potential therapeutic', 'target in autoimmune diseases? Pharmacologica reviews. 2010; 62(2): 199-236.', \"Smith TJ, Hoa N. Immunoglobulins from patients with Graves' disease induce hyaluronan\", 'synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I', 'receptor. The Journal of clinical endocrinology and metabolism. 2004; 89(10): 5076-80.', 'Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for Thyroid-Associated Ophthalmopathy.', 'The New England journal of medicine. 2017; 376(18): 1748-61.', 'Stan MN, Garrity JA, Carranza Leon BG, et al. Randomized controlled trial of rituximab in', \"patients with Graves' orbitopathy. The Journal of clinical endocrinology and metabolism. 2015;\", '100(2): 432-41.', \"Tanda ML, Piantanida E, Liparulo L, et al. Prevalence and natural history of Graves' orbitopathy\", \"in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center.\", 'The Journal of clinical endocrinology and metabolism. 2013; 98(4): 1443-9.', \"Terwee C, Wakelkamp I, Tan S, et al. Long-term effects of Graves' ophthalmopathy on health-\", 'related quality of life. European journal of endocrinology. 2002; 146(6): 751-7.', 'Terwee CB, Gerding MN, Dekker FW, et al. Development of a disease specific quality of life', \"questionnaire for patients with Graves' ophthalmopathy: the GO-QOL. The British journal of\", 'ophthalmology. 1998; 82(7): 773-9.', 'Tsui S, Naik V, Hoa N, et al. Evidence for an association between thyroid-stimulating hormone', \"and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease.\", 'Journal of immunology (Baltimore, Md : 1950). 2008; 181(6): 4397-405.', 'Ullrich A, Gray A, Tam AW, et al. Insulin-like growth factor I receptor primary structure:', 'comparison with insulin receptor suggests structural determinants that define functional', 'specificity. The EMBO journal. 1986; 5(10): 2503-12.', 'Weightman DR, Perros P, Sherif IH, et al. Autoantibodies to IGF-1 binding sites in thyroid', 'associated ophthalmopathy. Autoimmunity. 1993; 16(4): 251-7.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 114 of 118']\n\n###\n\n", "completion": "END"}